S. 2905Senate115th Congress (2017-2019)In Committee

Strengthening Partnerships to Prevent Opioid Abuse Act of 2018

Introduced May 22, 2018

AI-Generated Summary

Updated April 15, 2026 at 9:58 PM UTC

The Strengthening Partnerships to Prevent Opioid Abuse Act of 2018 amends the Social Security Act to improve transparency and coordination among Medicare Advantage and prescription drug plans in detecting and addressing opioid‑related fraud and overprescribing. It establishes a secure web portal for plans to report suspicious providers and share quarterly data on abuse trends, and it requires plans to include reporting on opioid prescribing in their contracts with the federal government. The changes affect Medicare Advantage organizations, prescription drug plans, and the federal agencies that oversee Medicare program integrity.

Key Provisions

  • Creates a secure online portal that Medicare Advantage (Part C) and prescription drug (Part D) plans must use to report and share information about providers suspected of fraud, waste, abuse, or overprescribing opioids.
  • Requires the Secretary of Health and Human Services to publish quarterly, anonymized reports to these plans showing trends and actions related to opioid overprescribing and other fraud schemes.
  • Mandates that, starting in plan years beginning Jan 1 2021, Medicare Advantage contracts must include a requirement for plans to submit evidence of suspected opioid overprescribing and any corrective actions they take.
  • Directs the Secretary to define “inappropriate prescribing of opioids” and set rules for how high‑volume prescribing is identified and reported.
  • Ensures that information shared through the portal does not prevent referrals to the HHS Inspector General or other law‑enforcement agencies.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateIntro Referral Latest Action

Read twice and referred to the Committee on Finance.

May 22, 2018

View full timeline
SenateIntro Referral

Introduced in Senate

May 22, 2018

SenateIntro Referral

Read twice and referred to the Committee on Finance.

May 22, 2018

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued May 22, 2018

II

115th CONGRESS

2d Session

S. 2905

IN THE SENATE OF THE UNITED STATES

May 22, 2018

Mr. Toomey (for himself and Mrs. McCaskill) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XVIII of the Social Security Act to provide for certain program integrity transparency measures under Medicare parts C and D.

1.

Short title

This Act may be cited as the Strengthening Partnerships to Prevent Opioid Abuse Act of 2018.

2.

Program integrity transparency measures under Medicare parts C and D

(a)

In general

Section 1859 of the Social Security Act (42 U.S.C. 1395w–28) is amended by adding at the end the following new subsection:

(i)

Program integrity transparency measures

(1)

Program integrity portal

(A)

In general

Not later than 2 years after the date of the enactment of this subsection, the Secretary shall, after consultation with stakeholders, establish a secure Internet website portal that would allow a secure path for communication between the Secretary, MA plans under this part, prescription drug plans under part D, and an eligible entity with a contract under section 1893 (such as a Medicare drug integrity contractor or any successor entity to a Medicare drug integrity contractor), in accordance with subsection (j)(3) of such section, for the purpose of enabling through such portal—

(i)

the referral by such plans of suspicious activities of a provider of services (including a prescriber) or supplier related to fraud, waste, and abuse for initiating or assisting investigations conducted by the eligible entity; and

(ii)

data sharing among such MA plans, prescription drug plans, and the Secretary (including with respect to information for activities under section 1893(j)).

(B)

Required uses of portal

The Secretary shall disseminate the following information to MA plans under this part and prescription drug plans under part D through the secure Internet website portal established under subparagraph (A):

(i)

Providers of services and suppliers that have been referred pursuant to subparagraph (A)(i) during the previous 12-month period.

(ii)

Providers of services and suppliers who are the subject of an active exclusion under section 1128 or who are subject to a suspension of payment under this title pursuant to section 1862(o) or otherwise.

(iii)

Providers of services and suppliers who are the subject of an active revocation of participation under this title, including for not satisfying conditions of participation.

(iv)

In the case of such a plan that makes a referral under subparagraph (A)(i) through the portal with respect to suspicious activities of a provider of services (including a prescriber) or supplier, if such provider (or prescriber) or supplier has been the subject of an administrative action under this title or title XI with respect to similar activities, a notification to such plan of such action so taken.

(C)

Rulemaking

For purposes of this paragraph, the Secretary shall, through rulemaking, specify what constitutes substantiated fraud, waste, and abuse, using guidance such as what is provided in the Medicare Program Integrity Manual 4.7.1.

(2)

Quarterly reports

Beginning not later than 2 years after the date of the enactment of this subsection, the Secretary shall make available to MA plans under this part and prescription drug plans under part D in a timely manner (but no less frequently than quarterly) and using information submitted to an entity described in paragraph (1) through the portal described in such paragraph or pursuant to section 1893, information on fraud, waste, and abuse schemes and trends in identifying suspicious activity. Information included in each such report shall—

(A)

include administrative actions, pertinent information related to opioid overprescribing, and other data determined appropriate by the Secretary in consultation with stakeholders; and

(B)

be anonymized information submitted by plans without identifying the source of such information.

(3)

Clarification

Nothing in this subsection shall preclude referrals to the Inspector General of the Department of Health and Human Services or other law enforcement entities.

.

(b)

Contract requirement To communicate plan corrective actions against opioids over-prescribers

Section 1857(e)(4)(C) of the Social Security Act (42 U.S.C. 1395w–27(e)(4)(C)) is amended by adding at the end the following new paragraph:

(5)

Communicating plan corrective actions against opioids over-prescribers

(A)

In general

Beginning with plan years beginning on or after January 1, 2021, a contract under this section with an MA organization shall require the organization to submit to the Secretary, through the process established under subparagraph (B), information on credible evidence of suspected fraud and other actions taken by such plans related to inappropriate prescribing of opioids.

(B)

Process

Not later than January 1, 2021, the Secretary shall, in consultation with stakeholders, establish a process under which MA plans and prescription drug plans shall submit to the Secretary information described in subparagraph (A).

(C)

Regulations

For purposes of this paragraph, including as applied under section 1860D–12(b)(3)(D), the Secretary shall, pursuant to rulemaking—

(i)

specify a definition for the term inappropriate prescribing of opioids and a method for determining if a provider of services prescribes such a high volume; and

(ii)

establish the process described in subparagraph (B) and the types of information that may be submitted through such process.

.

(c)

Reference under part D to program integrity transparency measures

Section 1860D–4 of the Social Security Act (42 U.S.C. 1395w–104) is amended by adding at the end the following new subsection:

(m)

Program integrity transparency measures

For program integrity transparency measures applied with respect to prescription drug plan and MA plans, see section 1859(i).

.